CDH1 and Proteus syndrome: Interestingly, the goals of the treatment of disorders such as Proteus syndrome would potentially align with our criteria for a chemopreventative strategy for patients lacking CDH1. Minimal toxicity is essential if ARQ-092 is to be used long-term.